<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04865562</url>
  </required_header>
  <id_info>
    <org_study_id>2015-02-0011</org_study_id>
    <nct_id>NCT04865562</nct_id>
  </id_info>
  <brief_title>Hormones and Decision Making</brief_title>
  <official_title>Hormones and Decision Making</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Texas at Austin</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Texas at Austin</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      An investigation of the neuropsychological processes underlying ethical decision making.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study will investigate the influence of reward sensitivity on cheating behavior via&#xD;
      experimental manipulation of reward sensitivity using testosterone.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 1, 2015</start_date>
  <completion_date type="Actual">September 1, 2016</completion_date>
  <primary_completion_date type="Actual">May 1, 2016</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Measure of ethical behavior - Cheating rate defined as the Average number of 'heads' coin flips participants claim to have obtained</measure>
    <time_frame>90 minutes</time_frame>
    <description>drug administration following by behavioral outcome. Specifically, participants will have the opportunity to predict the outcome of a series of coin flips. To obtain a measure of ethical behavior, participants will have the opportunity to cheat by over-reporting their prediction accuracy.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">30</enrollment>
  <condition>Dyssocial Behavior</condition>
  <arm_group>
    <arm_group_label>testosterone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>7mg testosterone propionate</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>125 mg 0.5% cholorbutanol, 50mg saline, pH5</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>testosterone propionate</intervention_name>
    <description>1mg/0.1mL solution, to be administered intranasally</description>
    <arm_group_label>testosterone</arm_group_label>
    <other_name>Testovis</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>0.5% cholorbutanol, saline</intervention_name>
    <description>125 mg 0.5% cholorbutanol, 50mg saline</description>
    <arm_group_label>placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  males between 18 and 25&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  recruitment will be limited to male participants between 18 and 25 years who have no&#xD;
             current conditions that would preclude the use of testosterone. Specific exclusion&#xD;
             criteria are:&#xD;
&#xD;
          -  women of all ages&#xD;
&#xD;
          -  males younger than 18 years and older than 25 years&#xD;
&#xD;
          -  self-report discomfort with ingestion of testosterone for the purpose of this study&#xD;
&#xD;
          -  body mass index lower than 18 or higher than 27&#xD;
&#xD;
          -  prior diagnosis of major depression, posttraumatic stress disorder, phobia, anxiety&#xD;
             disorder, or other psychiatric conditions&#xD;
&#xD;
          -  first-degree relatives diagnosed with a psychiatric disorder&#xD;
&#xD;
          -  presence of a medical condition that would preclude the use of testosterone&#xD;
&#xD;
          -  use of medications that would preclude the use of testosterone&#xD;
&#xD;
          -  consumption of more than 5 cigarettes a day&#xD;
&#xD;
          -  current use of testosterone enhancing products, such as gels, creams, and injections&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>25 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Robert A Josephs, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Texas at Austin</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Robert Josephs</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78712-1050</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>February 9, 2015</study_first_submitted>
  <study_first_submitted_qc>April 28, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">April 29, 2021</study_first_posted>
  <last_update_submitted>April 28, 2021</last_update_submitted>
  <last_update_submitted_qc>April 28, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 29, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Texas at Austin</investigator_affiliation>
    <investigator_full_name>Robert Josephs</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Antisocial Personality Disorder</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Methyltestosterone</mesh_term>
    <mesh_term>Testosterone</mesh_term>
    <mesh_term>Testosterone undecanoate</mesh_term>
    <mesh_term>Testosterone enanthate</mesh_term>
    <mesh_term>Testosterone 17 beta-cypionate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

